Lineage Cell Therapeutics Bolstered by Strategic Partnerships and Promising Trial Results, Analyst Reiterates Buy Rating with $9.00 Price Target.

Lineage Cell Therapeutics has a Buy rating from Joseph Pantginis at H.C. Wainwright, with a price target of $9.00. Pantginis cites strategic partnerships, including a $12 million deal with William Demant Invest A/S for its hearing loss program, and promising trial results for its OpRegen program in dry-AMD patients. The analyst expects potential funding from a CIRM grant and development milestones from Roche to strengthen Lineage's financial and strategic position. Pantginis has an average return of -7.9% and a 39.80% success rate.

Lineage Cell Therapeutics Inc. (LCTX) has received a Buy rating from Joseph Pantginis at H.C. Wainwright, with a price target of $9.00. Pantginis highlights strategic partnerships and promising trial results as key drivers for the company's potential growth.

The analyst cites a $12 million research collaboration with William Demant Invest A/S (WDI) for Lineage's auditory neuronal cell transplant, ReSonance (ANP1), for the treatment of hearing loss. This partnership, announced in late 2024, involves preclinical development activities and joint funding by WDI [2]. Additionally, Pantginis points to promising trial results for Lineage's OpRegen program in dry age-related macular degeneration (AMD) patients.

Pantginis expects potential funding from the California Institute for Regenerative Medicine (CIRM) and development milestones from Roche to further strengthen Lineage's financial and strategic position. The analyst's average return is -7.9%, with a 39.80% success rate [1].

In the last quarter, analysts' ratings for Lineage Cell Therapeutics varied from bullish to bearish, with one analyst maintaining a Buy rating and another maintaining a $9.00 price target [1]. This suggests a mix of optimism and caution among financial experts regarding the company's future prospects.

References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47366715/5-analysts-assess-lineage-cell-therapeutics-what-you-need-to-know
[2] https://www.marketscreener.com/news/lineage-cell-therapeutics-inc-announces-research-collaboration-with-william-demant-invest-to-devel-ce7c50ded98bf621